Core Points - Oculis Holding AG held its 2025 Annual General Meeting on June 4, 2025, where all agenda items were approved by shareholders [1] - The company reported a standalone statutory financial loss of CHF 5,179,000 for the financial year ended December 31, 2024, with an accumulated balance sheet loss of CHF 46,577,000 to be carried forward [2] - The Board of Directors and Executive Committee received discharge for their activities in 2024 [2] Board and Compensation - Anthony Rosenberg was re-elected as chairperson of the Board of Directors, along with the re-election of other board members and the Compensation Committee [3] - PricewaterhouseCoopers SA was re-elected as Statutory Auditors, and PST Legal AG was re-elected as Independent Proxy [3] - Shareholders approved the compensation for non-executive members of the Board of Directors and the Executive Committee, along with a non-binding advisory vote on the 2024 Compensation Report [4][8] Capital and Share Issuance - A capital band of 27,266,837 registered shares was approved, resulting in a capital band between CHF 545,336.74 and CHF 818,005.11 [5] - Conditional share capital for employees and individuals in comparable positions was approved, allowing for the issuance of 12,480,000 registered shares with a maximum amount of CHF 124,800 [6] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline including OCS-01 for diabetic macular edema, OCS-05 for acute optic neuritis, and OCS-02 for dry eye disease [7]

Core Insights - Capgemini has become the Official Technology Partner for the Tour de France and Tour de France Femmes avec Zwift until 2029, focusing on driving innovation in professional cycling through technology and AI [2][5][8] Group 1: Partnership Details - The partnership includes 14 international cycling events, such as La Vuelta, Paris-Roubaix, and five standalone women's races, enhancing the global cycling community [2][4] - Capgemini will leverage its expertise in digital innovation and AI to support these events over the next five years, aiming to enhance performance insights and engage fans [5][6] Group 2: Impact on Fan Engagement - In 2024, the Tour de France achieved over 1 billion TV viewed hours across 190 countries, with nearly 100 million website visits and 1.6 billion social media impressions, indicating a strong fan engagement potential [5] - The partnership aims to promote new digital solutions to enhance the fan experience and engage new communities [8][9] Group 3: Capgemini's Broader Strategy - This partnership expands Capgemini's sports sponsorship portfolio, emphasizing technological innovation and high performance [6][7] - Capgemini operates in over 50 countries, targeting regions with strong cycling fanbases, which will help promote the cycling events internationally [6][10]

Group 1 - The issuer, UAB "Kvartalas", has decided to end the subscription process for the offering of the 3rd tranche of bonds due to sufficient investor demand [1] - As of the announcement time, Nasdaq Exchange Members will not accept any new subscription orders from investors, and only previously received buy orders can be entered into the Exchange Trading System until 12:00 midday [2] - The results of the offering for the 3rd tranche of bonds will be announced publicly in a separate notice [3]

Core Insights - Atos has been appointed as the Official Information Technology Partner for the UEFA Nations League Finals™ 2025, scheduled from June 4 to June 8, 2025, in Germany, providing essential IT services and applications support [1] - The partnership aims to enhance the experience for all stakeholders, including fans and media, by managing core IT planning and operations systems with a focus on reliability, efficiency, and security [2] - Atos has a history of successful collaboration with UEFA, having supported over 200 applications and a cumulative live audience of over 5 billion during UEFA EURO 2024™ [3] Company Overview - Atos has over 30 years of experience in serving partners and customers through its dedicated sports and major events division, demonstrating flexibility and expertise in technology solutions [7] - The company has been involved with the Olympic and Paralympic Movements since 1992 and 2002 respectively, and serves as the Official Digital Technology Partner for various international sporting events [8] - Atos Group operates with approximately 72,000 employees and annual revenue of around €10 billion, focusing on digital transformation, cybersecurity, cloud services, and high-performance computing [11]

Group 1 - Municipality Finance Plc issued NOK 2 billion notes with a fixed interest rate of 4.125% per annum, maturing on 6 January 2031 [1] - The notes are part of MuniFin's EUR 50 billion debt issuance program, with public trading expected to commence on 6 June 2025 on the Helsinki Stock Exchange [2] - DNB Bank ASA is acting as the dealer for the issuance of these notes [3] Group 2 - MuniFin is one of Finland's largest credit institutions, with a balance sheet exceeding EUR 53 billion, owned by Finnish municipalities, the public sector pension fund Keva, and the State of Finland [3] - The company focuses on environmentally and socially responsible investments, lending to municipalities and non-profit organizations for projects like public transportation, sustainable buildings, and healthcare facilities [4] - MuniFin operates in a global business environment and is recognized as the first Finnish issuer of green and social bonds, with funding guaranteed by the Municipal Guarantee Board [5]

Core Viewpoint - Alvotech and Dr. Reddy's Laboratories have entered a collaboration to co-develop a biosimilar candidate to Keytruda® (pembrolizumab), which had worldwide sales of US$29.5 billion in 2024, aiming to enhance the availability of cost-effective biologic medications for cancer treatment globally [1][2][3][4]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, with a goal to be a leader in the biosimilar space by providing high-quality, cost-effective products [7]. - Dr. Reddy's Laboratories is a global pharmaceutical company committed to providing access to affordable and innovative medicines, with a focus on various therapeutic areas including oncology [10][11]. Collaboration Details - The collaboration agreement stipulates that both companies will share responsibilities and costs in the development and manufacturing of the biosimilar candidate, with each party having the right to commercialize the product globally [2]. - This partnership is expected to leverage the strengths of both companies in biosimilars, accelerating the development process and expanding market reach [1][3][4]. Market Context - Keytruda® is a critical therapy in immuno-oncology, and the collaboration aims to enhance the capabilities of both companies in this therapeutic area [4]. - The biosimilars market is growing, and this collaboration positions both companies to capitalize on the increasing demand for affordable cancer treatments [3][4].

Core Insights - Richemont has published its combined Annual Report and Non-Financial Report for the fiscal year ending March 31, 2025, which includes comprehensive financial statements and governance details [3][4]. Financial Reporting - The Annual Report includes the Chairman's review, consolidated financial statements, and audit reports, previously released on May 16, 2025 [3]. - The Non-Financial Report adheres to the Global Reporting Initiative (GRI) Standards and complies with Swiss Code of Obligations, including climate disclosures [4]. Availability of Reports - Both reports are accessible for download on Richemont's official website, with hard copies available upon request [5]. - In South Africa, the reports can be obtained directly from the Depository Agent, Computershare Investor Services [6]. Company Overview - Richemont is known for its prestigious Maisons, focusing on craftsmanship and creativity, with a commitment to sustainable growth [7]. - The company operates in three main business areas: Jewellery Maisons, Specialist Watchmakers, and Fashion & Accessories Maisons [8]. Stock Information - Richemont A shares are listed on the SIX Swiss Exchange and included in the Swiss Market Index (SMI), with a secondary listing on the Johannesburg Stock Exchange [9].

Company Overview - Ageas Re, the reinsurance arm of Ageas Group, has entered into a reinsurance agreement with Slovenian insurer Triglav Group to enhance its business portfolio and support Ageas's Elevate27 growth strategy [1][3] - Triglav Group is the largest insurance-financial group in the Adria region and operates in six countries, focusing on insurance and asset management [7] - Prima Assicurazioni, a rapidly growing insurtech company, has become the number one direct Motor insurance distributor in Italy since its inception in 2015, generating EUR 1.3 billion in gross written premiums in 2024 [2][6] Partnership Details - Under the agreement, Ageas Re will take an 80% Quota Share on the Prima business underwritten by Triglav Group starting in 2025 [2] - The partnership aims to leverage the tech-driven capabilities of Prima to achieve profitable growth in the attractive European Non-Life insurance market, which generates over EUR 15 billion in premiums [3] Financial Projections - Ageas Re anticipates inflows exceeding EUR 500 million from this transaction in 2025, with a projected Net Operating Result of around EUR 15 million spread over 2025 and 2026 [4] - The impact on Group Solvency is estimated to be no more than -4 points in 2025 [4] Strategic Alignment - The agreement aligns with Ageas's Elevate27 strategy, which focuses on profitable growth in the European Non-Life market [3][5] - Triglav Group aims to enhance its international recognition and expand beyond existing markets through this partnership [5][7]

Company Overview - Terranet AB focuses on developing innovative technical solutions for Advanced Driver Assistance Systems (ADAS) and Autonomous Vehicles (AV) aimed at enhancing urban traffic safety [7] - The company is headquartered in Lund, Sweden, with additional offices in Gothenburg and Stuttgart, and has been listed on Nasdaq First North Premier Growth Market since 2017 [8] Rights Issue Details - The Rights Issue involves a maximum of 13,880,714 units, with each unit consisting of twelve B-shares and three warrants of series TO9 B, issued free of charge [9] - The subscription price is set at SEK 1.08 per unit, equating to SEK 0.09 per B-share, and is expected to raise approximately SEK 15 million before costs [9] - Shareholders will have preferential rights to subscribe, with one existing share granting one unit right, and eighty-six unit rights needed to subscribe for one unit [9] - The subscription period runs from May 27, 2025, to June 11, 2025, with trading in unit rights occurring from May 27, 2025, to June 5, 2025 [4][9] Financial Commitments - The Rights Issue is fully covered by subscription commitments of approximately SEK 35.2 thousand (0.2% of the Rights Issue) and underwriting commitments of about SEK 15 million (99.8% of the Rights Issue), totaling 100% coverage [9]

Core Insights - Kalmar has secured a significant order to supply 11 hybrid straddle carriers to Seayard for the FOS2 XL container terminal in Fos-sur-Mer, France, with delivery expected by Q2 2026 [1][3]. Company Overview - Kalmar is a global leader in sustainable material handling equipment and services, headquartered in Helsinki, Finland, operating in over 120 countries with approximately 5,200 employees. In 2024, Kalmar's sales reached approximately EUR 1.7 billion [5]. Environmental Impact - The new hybrid straddle carriers will enable Seayard to significantly reduce fuel consumption and CO2 emissions compared to traditional diesel-powered machines, while also generating less noise [3]. Operational Efficiency - The MyKalmar INSIGHT performance management tool will provide Seayard with actionable insights to enhance fleet operations and identify efficiency improvement areas [3][4]. Strategic Partnership - The partnership between Kalmar and Seayard is strengthened through this order, with a focus on optimizing fuel consumption and improving operational reliability [4].